Cancilico receives 2.5 million euros for AI-supported bone marrow diagnostics

The Dresden-based health tech start-up Cancilico, which specializes in blood cancer diagnostics, has successfully completed a seed financing round of 2.5 million euros. The funds are intended to accelerate the scaling of the AI-based diagnostic software MyeloAID in order to make blood cancer diagnoses more precise and faster worldwide.

Strong investor consortium supports growth

The round is led by renowned investors such as High-Tech Gründerfonds (HTGF), TGFS - Technologiegründerfonds Sachsen, GEDAD GmbH and ROI Verwaltungsgesellschaft (Roland Oetker).

We are investing in an outstanding team and a superior technology that is already showing commercial success. Cancilico combines entrepreneurial spirit with deep technical and clinical knowledge.

Dr. Jörg Traub, HTGF

AI is changing the diagnosis of hematologic diseases

The MyeloAID software uses advanced AI to analyze bone marrow samples faster and more precisely than conventional methods. The AI draws on extensive, validated data sets from both healthy and diseased patients. Partnerships with hematopathology centers are continuously expanding the database.

A key advantage is that the technology is platform-independent and can be used on existing microscopes and scanners without the need for expensive hardware upgrades. MyeloAID is currently already available as Research Use Only (RUO) via the PathoZoom® Scan & LiveView Suite.

Broad access to expert diagnostics

Cancilico is responding to the global shortage of hematologists and increasing case numbers in diagnostics.

This investment enables us to overcome regulatory hurdles and develop a tool that gives laboratories access to expert-level diagnostics without high costs.

Markus Badstübner, CEO Cancilico

The funding will also drive the development of digital biomarkers and improve precision medicine for blood cancer patients worldwide.

Founded in Dresden in 2023, Cancilico combines data science and clinical hematology. The team comprises Markus Badstübner (CEO), Dr. Moritz Middeke (CMO), Tim Schmittmann, Sebastian Riechert, Dr. Jan Eckardt, Dr. Karsten Wendt and angel investor Prof. Gerhard Ehninger. The start-up is part of the Saxon life science ecosystem and works closely with Biosaxony and the Clusters4Future initiatives SaxoCell and SEMECO.